Table 5. The characteristics of the included studies with the concordance rate between WFO and MDT in different stages and subtypes.
| Authors | Publication year | Country | Number of cases (M/F) | Median age (range), years | Subtypes (cases) | Stage I NSCLC | Stage II NSCLC | Stage III NSCLC | Stage IV NSCLC | ADC | SCC | SCLC | Overall |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Kim et al. (51) | 2020 | Korea | 405 (340/65) | 71 (37–88) | ADC (n=157); SCC (n=132); SCLC (n=94); Other (n=22) |
NR | NR | NR | NR | 94.90% | 90.20% | 97.90% | 92.40% |
| You et al. (52) | 2020 | China | 310 (215/95) | NR | ADC (n=217); SCC (n=91); LC (n=2) |
NR | NR | NR | NR | 87.56% | 79.12% | – | 85.16% |
| Yao et al. (54) | 2020 | China | 165 (109/56) | NR | ADC (n=121); SCC (n=43); ASC (n=1) |
Stage ≤III: 77.8% | 93.50% | 90.50% | 90.70% | – | 73.30% | ||
| Liu et al. (53) | 2018 | China | 149 (124/25) | 60 (26–83) | ADC (n=61); SCC (n=61); SCLC (n=23); LC (n=1); ASC (n=3) |
83% | 59% | 42% | 89% | NSCLC: 61.1% | 83% | 81.90% | |
NR, not reported; MDT, the multidisciplinary team; WFO, Watson for Oncology; ADC, adenocarcinoma; SCC, squamous-cell carcinoma; NSCLC, non-small cell lung cancer; SCLC, small cell lung cancer; ASC, adenosquamous carcinoma; LC, large cell lung cancer.